MENLO PARK, CA--(Marketwire - October 25, 2007) - SRI International, an independent nonprofit research and development organization, today announced that it has been awarded a $7.9 million contract by the National Cancer Institute (NCI) to conduct analytical chemistry evaluations of anti-cancer drugs and dosage formulations. The new contract, which was awarded to SRI by the NCI's Pharmaceutical Resources Branch as part of their Developmental Therapeutics Program, aims to further the development of promising compounds by providing resources to investigators developing new therapies.
